Skip to main content
OpenTrials
Completed

NCT Number: NCT00190060

Study of The Effects of Testosterone in Frail Elderly Men

The study aims to determine the effects of testosterone on muscle function, mobility, activities of daily living and overall quality of life

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary

Manchester, M13 9WL, United Kingdom

About this study

Ageing-associated loss of muscle mass and strength is a major cause of physical frailty, disability, morbidity and dependency in the elderly. This is associated with increased falls, fractures, loss of mobility, restricted activities of daily living and increased utilisation of healthcare resources. It is well known that serum testosterone levels fall with advancing age and this may be an important cause for muscle wasting and weakness (sarcopenia). Testosterone replacement increases muscle mass and improves muscle strength in young hypogonadal men. In relatively healthy elderly men, some short-term studies have also shown that testosterone can improve muscle strength. The potential beneficial effects of testosterone supplementation on muscle strength and functional capacity of frail elderly men has so far not been studies and forms the basis of this research. We hypothesise that testosterone supplementation is an effective, safe and economic anabolic intervention in frail elderly men with low circulating testosterone.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Frail elderly men (as defined by Freid's criteria of frailty)
  • Community - dwelling men aged 65 years and above
  • Total testosterone ≤12.0 nmol/L or calculated free T≤0.25nmol/L

Exclusion criteria

  • Carcinoma of prostate
  • Carcinoma of breast
  • PSA >4ng/mL
  • Severe symptomatic benign prostatic hypertrophy (IPSS >21)
  • Active liver disease
  • Renal impairment (serum creatinine >180 mmol/L)
  • Congestive heart failure
  • Unstable ischaemic heart disease
  • Polycythaemia
  • Evidence of systemic disease which may affect muscle/joint function
  • Moderate to severe peripheral vascular disease
  • Moderate to severe chronic obstructive airways disease
  • Alcohol consumption over 30 units per week
  • Medications that interfere with sex steroid metabolism
  • History of stroke causing persistent motor deficit
  • Cognitive deficit
  • Major psychiatric illness
  • Hospital admission in the past 6 weeks
  • Sleep apnoea

Treatment and study plan

Transdermal testosterone gel (Testogel 1% )

Drug

Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months

Other names: Testogel 1%

Matched transdermal placebo gel

Drug

Matched transdermal placebo gel, 50mg/d for 6 months

Primary outcomes

  1. Lower limb muscle strength at 6 months

    Time frame: 6 months

Secondary outcomes

  1. Upper limb muscle strength at 6 months

    Time frame: 6 months

  2. Quality of life at 6 months

    Time frame: 6 months

  3. Total and regional lean body mass at 6 months

    Time frame: 6 months

  4. Improvement in physical performance

    Time frame: 6 months

  5. Bone Mineral Density

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Manchester University NHS Foundation Trust

Other Gov

Collaborators

  • Bayer
  • University of Manchester

Registry information

Official study title

Study of The Effects of Testosterone on Muscle Function, Physical Performance, Body Composition and Quality of Life in Frail Elderly Men

Important dates

Study start
2004
Primary completion
2008
Study completion
2008
First posted
Sep 19, 2005
Registry last updated
Aug 3, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.